Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Peking University Cancer Hospital & Institute: Clinical Trials & FDA Approval Profile

Peking University Cancer Hospital & Institute (Global / Institutional) sponsors 91 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 54 active protocols (22 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.1%
Median Closed Enrollment vs National (145 pts)22 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Peking University Cancer Hospital & Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)91
Active Pipeline (Recruiting Now)54 (22)
Completed vs Stopped Early4 / 1 (1.1%)
Median Closed Actual Enrollment22 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Peking University Cancer Hospital & Institute
Hospital Research SiteLocationShared Protocols
Beijing Cancer HospitalBeijing, Beijing Municipality40
Peking University Cancer HospitalBeijing10

Explore interactive annual charts and M&A subsidiary rollups in the Peking University Cancer Hospital & Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI